https://trial.medpath.com/news/airnexis-therapeutics-secures-200m-series-a-to-advance-dual-pde3-4-inhibitor-for-copd-treatment 2026-01-09T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airnexis-therapeutics-secures-200m-series-a-to-advance-dual-pde3-4-inhibitor-for-copd-treatment 2026-01-09T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/enodia-therapeutics-secures-eur20-7m-seed-funding-to-advance-novel-protein-degradation-platform-targeting-sec61-translocon 2026-01-09T16:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enodia-therapeutics-secures-eur20-7m-seed-funding-to-advance-novel-protein-degradation-platform-targeting-sec61-translocon 2026-01-09T16:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/ping-an-biomedical-secures-90-million-in-strategic-investments-to-accelerate-biopharmaceutical-innovation 2026-01-09T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ping-an-biomedical-secures-90-million-in-strategic-investments-to-accelerate-biopharmaceutical-innovation 2026-01-09T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-advances-iopofosine-i-131-toward-european-approval-for-waldenstrom-s-macroglobulinemia 2026-01-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-advances-iopofosine-i-131-toward-european-approval-for-waldenstrom-s-macroglobulinemia 2026-01-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/newamsterdam-pharma-advances-obicetrapib-development-with-promising-alzheimer-s-biomarker-data-and-multiple-phase-3-trials 2026-01-09T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newamsterdam-pharma-advances-obicetrapib-development-with-promising-alzheimer-s-biomarker-data-and-multiple-phase-3-trials 2026-01-09T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-reports-strong-brinsupri-launch-with-144-6m-first-quarter-revenue-advances-multiple-phase-3-programs 2026-01-09T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-reports-strong-brinsupri-launch-with-144-6m-first-quarter-revenue-advances-multiple-phase-3-programs 2026-01-09T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-reports-strong-commercial-launch-progress-for-vykat-xr-in-prader-willi-syndrome 2026-01-09T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soleno-therapeutics-reports-strong-commercial-launch-progress-for-vykat-xr-in-prader-willi-syndrome 2026-01-09T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-camurus-resubmitted-nda-for-oclaiz-acromegaly-treatment-with-june-2026-pdufa-date 2026-01-09T16:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-camurus-resubmitted-nda-for-oclaiz-acromegaly-treatment-with-june-2026-pdufa-date 2026-01-09T16:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-outlines-2026-strategic-priorities-with-focus-on-melanoma-franchise-expansion-and-pipeline-advancement 2026-01-09T15:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-outlines-2026-strategic-priorities-with-focus-on-melanoma-franchise-expansion-and-pipeline-advancement 2026-01-09T15:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/a2-biotherapeutics-receives-fda-clearance-for-a2b543-car-t-therapy-with-il-12-booster-for-advanced-solid-tumors 2026-01-09T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a2-biotherapeutics-receives-fda-clearance-for-a2b543-car-t-therapy-with-il-12-booster-for-advanced-solid-tumors 2026-01-09T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-reports-strong-yutrepia-launch-with-148-3m-in-full-year-2025-sales-expands-clinical-pipeline 2026-01-09T15:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-reports-strong-yutrepia-launch-with-148-3m-in-full-year-2025-sales-expands-clinical-pipeline 2026-01-09T15:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/huons-biopharma-s-hutox-becomes-seventh-botulinum-toxin-approved-in-china-following-nmpa-authorization 2026-01-09T15:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-biopharma-s-hutox-becomes-seventh-botulinum-toxin-approved-in-china-following-nmpa-authorization 2026-01-09T15:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-achieves-complete-b-cell-depletion-in-non-human-primates-with-in-vivo-car-t-platform 2026-01-09T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/create-medicines-achieves-complete-b-cell-depletion-in-non-human-primates-with-in-vivo-car-t-platform 2026-01-09T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-expands-leadership-and-research-partnerships-to-advance-live-tumor-immunotherapy-platform 2026-01-09T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elephas-biosciences-expands-leadership-and-research-partnerships-to-advance-live-tumor-immunotherapy-platform 2026-01-09T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/collegium-pharmaceutical-secures-980-million-credit-facility-and-authorizes-generic-nucynta-launch 2026-01-09T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collegium-pharmaceutical-secures-980-million-credit-facility-and-authorizes-generic-nucynta-launch 2026-01-09T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-receives-fda-ind-clearance-for-phase-2b-trial-of-mh002-live-biotherapeutic-in-ulcerative-colitis 2026-01-09T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrm-health-receives-fda-ind-clearance-for-phase-2b-trial-of-mh002-live-biotherapeutic-in-ulcerative-colitis 2026-01-09T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-advances-amx0318-as-long-acting-glp-1-receptor-antagonist-for-post-bariatric-hypoglycemia 2026-01-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-advances-amx0318-as-long-acting-glp-1-receptor-antagonist-for-post-bariatric-hypoglycemia 2026-01-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/medilink-and-roche-expand-partnership-with-570-million-deal-for-b7h3-targeting-adc-yl201 2026-01-09T05:58:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medilink-and-roche-expand-partnership-with-570-million-deal-for-b7h3-targeting-adc-yl201 2026-01-09T05:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/entrada-therapeutics-advances-rna-based-pipeline-with-first-ocular-candidate-for-usher-syndrome 2026-01-09T01:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entrada-therapeutics-advances-rna-based-pipeline-with-first-ocular-candidate-for-usher-syndrome 2026-01-09T01:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-launches-first-commercial-integration-of-one-year-cgm-with-automated-insulin-delivery-system 2026-01-09T01:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-launches-first-commercial-integration-of-one-year-cgm-with-automated-insulin-delivery-system 2026-01-09T01:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/mit-engineers-develop-biodegradable-smart-pills-that-report-medication-intake-to-healthcare-providers 2026-01-09T01:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-engineers-develop-biodegradable-smart-pills-that-report-medication-intake-to-healthcare-providers 2026-01-09T01:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/osel-launches-first-ever-pivotal-trial-of-microbiome-based-cancer-therapy-mo-03-for-advanced-renal-cell-carcinoma 2026-01-09T01:01:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osel-launches-first-ever-pivotal-trial-of-microbiome-based-cancer-therapy-mo-03-for-advanced-renal-cell-carcinoma 2026-01-09T01:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/acuitas-therapeutics-acquires-majority-stake-in-rna-technologies-therapeutics-to-advance-rna-lnp-therapeutics 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acuitas-therapeutics-acquires-majority-stake-in-rna-technologies-therapeutics-to-advance-rna-lnp-therapeutics 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/one-genomics-partners-with-cira-foundation-to-advance-high-precision-crispr-technology-for-regenerative-medicine 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-genomics-partners-with-cira-foundation-to-advance-high-precision-crispr-technology-for-regenerative-medicine 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/enliven-therapeutics-reports-promising-phase-1b-results-for-elvn-001-in-treatment-resistant-chronic-myeloid-leukemia 2026-01-09T00:59:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enliven-therapeutics-reports-promising-phase-1b-results-for-elvn-001-in-treatment-resistant-chronic-myeloid-leukemia 2026-01-09T00:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-and-veeva-systems-expand-strategic-partnership-to-accelerate-rare-disease-drug-development 2026-01-09T00:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-and-veeva-systems-expand-strategic-partnership-to-accelerate-rare-disease-drug-development 2026-01-09T00:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/tecregen-secures-eur11m-seed-funding-and-appoints-new-ceo-to-advance-thymus-regeneration-therapeutics 2026-01-09T00:59:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tecregen-secures-eur11m-seed-funding-and-appoints-new-ceo-to-advance-thymus-regeneration-therapeutics 2026-01-09T00:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-class-non-opioid-journavx-for-acute-pain-marking-20-year-breakthrough 2026-01-09T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-in-class-non-opioid-journavx-for-acute-pain-marking-20-year-breakthrough 2026-01-09T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/ubc-researchers-achieve-breakthrough-in-stem-cell-derived-helper-t-cell-production-for-cancer-therapy 2026-01-09T00:58:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubc-researchers-achieve-breakthrough-in-stem-cell-derived-helper-t-cell-production-for-cancer-therapy 2026-01-09T00:58:05+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-demonstrate-first-successful-personalized-cancer-treatment-based-on-tumor-dna 2026-01-09T00:58:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-san-diego-researchers-demonstrate-first-successful-personalized-cancer-treatment-based-on-tumor-dna 2026-01-09T00:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-names-rick-suarez-us-president-to-lead-50-billion-investment-strategy 2026-01-08T21:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-names-rick-suarez-us-president-to-lead-50-billion-investment-strategy 2026-01-08T21:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-s-synaffix-partners-with-sidewinder-therapeutics-to-develop-next-generation-bispecific-adcs-for-solid-tumors 2026-01-08T21:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-s-synaffix-partners-with-sidewinder-therapeutics-to-develop-next-generation-bispecific-adcs-for-solid-tumors 2026-01-08T21:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/santhera-secures-swiss-approval-for-agamree-as-nxera-expands-asia-pacific-access-for-duchenne-muscular-dystrophy-treatment 2026-01-08T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santhera-secures-swiss-approval-for-agamree-as-nxera-expands-asia-pacific-access-for-duchenne-muscular-dystrophy-treatment 2026-01-08T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/acousia-therapeutics-completes-enrollment-in-phase-2-trial-testing-acou085-for-cisplatin-induced-hearing-loss 2026-01-08T21:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acousia-therapeutics-completes-enrollment-in-phase-2-trial-testing-acou085-for-cisplatin-induced-hearing-loss 2026-01-08T21:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-partners-with-panther-to-advance-africa-cdc-led-mpox-treatment-trial 2026-01-08T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergent-biosolutions-partners-with-panther-to-advance-africa-cdc-led-mpox-treatment-trial 2026-01-08T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/alveus-therapeutics-emerges-with-160m-to-develop-next-generation-obesity-therapies 2026-01-08T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alveus-therapeutics-emerges-with-160m-to-develop-next-generation-obesity-therapies 2026-01-08T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/abbelight-secures-series-b-funding-to-expand-super-resolution-microscopy-technology-for-drug-discovery-applications 2026-01-08T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbelight-secures-series-b-funding-to-expand-super-resolution-microscopy-technology-for-drug-discovery-applications 2026-01-08T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/intent-biologics-receives-fda-fast-track-designation-for-first-in-class-exosome-therapy-for-diabetic-foot-ulcers 2026-01-08T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intent-biologics-receives-fda-fast-track-designation-for-first-in-class-exosome-therapy-for-diabetic-foot-ulcers 2026-01-08T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/renexxion-secures-sixth-u-s-patent-for-naronapride-trihydrate-formulation-targeting-multiple-gi-disorders 2026-01-08T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renexxion-secures-sixth-u-s-patent-for-naronapride-trihydrate-formulation-targeting-multiple-gi-disorders 2026-01-08T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-advances-t-cell-engagers-to-phase-2-studies-for-autoimmune-diseases 2026-01-08T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candid-therapeutics-advances-t-cell-engagers-to-phase-2-studies-for-autoimmune-diseases 2026-01-08T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-launches-phase-1-trial-of-agent-797-for-graft-versus-host-disease-prevention 2026-01-08T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-launches-phase-1-trial-of-agent-797-for-graft-versus-host-disease-prevention 2026-01-08T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-launches-phase-1-trial-of-oral-glp-1-glp-2-dual-agonist-rt-114-for-obesity-treatment 2026-01-08T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rani-therapeutics-launches-phase-1-trial-of-oral-glp-1-glp-2-dual-agonist-rt-114-for-obesity-treatment 2026-01-08T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-platform-identifies-pancreatic-cancer-patient-subgroup-with-threefold-survival-improvement 2026-01-08T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-platform-identifies-pancreatic-cancer-patient-subgroup-with-threefold-survival-improvement 2026-01-08T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/glycoera-appoints-petra-duda-as-chief-medical-officer-to-lead-precision-protein-degrader-pipeline 2026-01-08T21:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycoera-appoints-petra-duda-as-chief-medical-officer-to-lead-precision-protein-degrader-pipeline 2026-01-08T21:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-reports-positive-preliminary-results-for-cannabinoid-based-cancer-pain-treatment 2026-01-08T21:00:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-reports-positive-preliminary-results-for-cannabinoid-based-cancer-pain-treatment 2026-01-08T21:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-combination-therapy-shows-superior-efficacy-in-first-of-kind-trial-for-psoriatic-arthritis-patients-with-obesity 2026-01-08T21:00:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-combination-therapy-shows-superior-efficacy-in-first-of-kind-trial-for-psoriatic-arthritis-patients-with-obesity 2026-01-08T21:00:23+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-reports-positive-phase-1-safety-data-for-rna-editing-therapy-ax-0810-advances-pipeline-programs 2026-01-08T21:00:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-reports-positive-phase-1-safety-data-for-rna-editing-therapy-ax-0810-advances-pipeline-programs 2026-01-08T21:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-therapeutics-strengthens-leadership-team-with-new-chief-commercial-officer-and-board-restructuring 2026-01-08T21:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-therapeutics-strengthens-leadership-team-with-new-chief-commercial-officer-and-board-restructuring 2026-01-08T21:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-initiates-two-phase-1-trials-expanding-oncology-pipeline-with-abbv-901-and-abbv-243 2026-01-08T21:00:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-initiates-two-phase-1-trials-expanding-oncology-pipeline-with-abbv-901-and-abbv-243 2026-01-08T21:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-partners-with-boltz-to-integrate-ai-models-into-drug-discovery-pipeline 2026-01-08T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-partners-with-boltz-to-integrate-ai-models-into-drug-discovery-pipeline 2026-01-08T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/enyo-pharma-s-vonafexor-reverses-kidney-function-decline-in-phase-2-alport-syndrome-trial 2026-01-08T20:59:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enyo-pharma-s-vonafexor-reverses-kidney-function-decline-in-phase-2-alport-syndrome-trial 2026-01-08T20:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/critics-ii-trial-identifies-optimal-preoperative-strategy-for-resectable-gastric-cancer 2026-01-08T20:59:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/critics-ii-trial-identifies-optimal-preoperative-strategy-for-resectable-gastric-cancer 2026-01-08T20:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/varmx-and-rentschler-biopharma-expand-partnership-for-phase-iii-development-of-novel-coagulation-therapy-vmx-c001 2026-01-08T20:59:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varmx-and-rentschler-biopharma-expand-partnership-for-phase-iii-development-of-novel-coagulation-therapy-vmx-c001 2026-01-08T20:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-launches-early-access-program-for-single-molecule-proteomics-platform-with-tau-proteoforms-assay 2026-01-08T20:59:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nautilus-biotechnology-launches-early-access-program-for-single-molecule-proteomics-platform-with-tau-proteoforms-assay 2026-01-08T20:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/engitix-secures-eur21-million-series-a-extension-to-advance-ecm-targeted-cancer-and-fibrosis-therapies 2026-01-08T20:59:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engitix-secures-eur21-million-series-a-extension-to-advance-ecm-targeted-cancer-and-fibrosis-therapies 2026-01-08T20:59:17+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-and-ksilink-partner-to-screen-nanocyclix-r-library-for-cns-therapeutics 2026-01-08T20:59:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-and-ksilink-partner-to-screen-nanocyclix-r-library-for-cns-therapeutics 2026-01-08T20:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-alessa-s-enolen-for-localized-prostate-cancer-treatment 2026-01-08T20:57:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-alessa-s-enolen-for-localized-prostate-cancer-treatment 2026-01-08T20:57:56+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-submits-first-ever-targeted-therapy-for-guillain-barre-syndrome-to-european-regulators 2026-01-08T20:57:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-submits-first-ever-targeted-therapy-for-guillain-barre-syndrome-to-european-regulators 2026-01-08T20:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/yale-study-reveals-gsk3b-inhibitors-as-promising-treatment-for-relapsed-b-cell-acute-lymphoblastic-leukemia 2026-01-08T20:57:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-study-reveals-gsk3b-inhibitors-as-promising-treatment-for-relapsed-b-cell-acute-lymphoblastic-leukemia 2026-01-08T20:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-secures-50-million-financing-to-advance-first-potential-treatment-for-sanfilippo-syndrome-type-b 2026-01-08T18:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-secures-50-million-financing-to-advance-first-potential-treatment-for-sanfilippo-syndrome-type-b 2026-01-08T18:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-advances-masked-adc-varsetatug-masetecan-toward-registrational-trial-in-colorectal-cancer 2026-01-08T18:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-advances-masked-adc-varsetatug-masetecan-toward-registrational-trial-in-colorectal-cancer 2026-01-08T18:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/ardelyx-reports-strong-2025-performance-with-ibsrela-revenue-growing-73-and-launches-phase-3-trial-for-chronic-constipation 2026-01-08T18:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ardelyx-reports-strong-2025-performance-with-ibsrela-revenue-growing-73-and-launches-phase-3-trial-for-chronic-constipation 2026-01-08T18:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-secures-35-8m-funding-advances-masked-immuno-oncology-pipeline-with-key-development-milestones 2026-01-08T18:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xilio-therapeutics-secures-35-8m-funding-advances-masked-immuno-oncology-pipeline-with-key-development-milestones 2026-01-08T18:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-secures-305-million-series-f-to-advance-first-in-class-b-catenin-inhibitor-zolucatetide 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parabilis-medicines-secures-305-million-series-f-to-advance-first-in-class-b-catenin-inhibitor-zolucatetide 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/diagonal-therapeutics-secures-125m-series-b-to-advance-first-in-class-clustering-antibody-diag723-for-rare-genetic-diseases 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagonal-therapeutics-secures-125m-series-b-to-advance-first-in-class-clustering-antibody-diag723-for-rare-genetic-diseases 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-advances-haduvio-development-with-fda-end-of-phase-2-meeting-and-phase-2b-trial-plans-for-chronic-cough-treatment 2026-01-08T18:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trevi-therapeutics-advances-haduvio-development-with-fda-end-of-phase-2-meeting-and-phase-2b-trial-plans-for-chronic-cough-treatment 2026-01-08T18:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-therapeutics-advances-two-next-generation-adcs-into-clinical-trials-with-fda-ind-clearances 2026-01-08T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whitehawk-therapeutics-advances-two-next-generation-adcs-into-clinical-trials-with-fda-ind-clearances 2026-01-08T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-advances-multi-drug-pipeline-with-phase-2-trial-initiation-and-2026-data-readouts-expected 2026-01-08T18:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/climb-bio-advances-multi-drug-pipeline-with-phase-2-trial-initiation-and-2026-data-readouts-expected 2026-01-08T18:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/atsena-therapeutics-completes-phase-i-ii-dosing-for-xlrs-gene-therapy-advances-to-pivotal-trial 2026-01-08T18:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atsena-therapeutics-completes-phase-i-ii-dosing-for-xlrs-gene-therapy-advances-to-pivotal-trial 2026-01-08T18:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/fox-chase-cancer-center-becomes-first-nci-designated-center-to-implement-3d-genome-diagnostics-for-cancer-care 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fox-chase-cancer-center-becomes-first-nci-designated-center-to-implement-3d-genome-diagnostics-for-cancer-care 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-agrees-to-4-00-per-share-acquisition-by-kuva-labs-in-85-premium-deal 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-agrees-to-4-00-per-share-acquisition-by-kuva-labs-in-85-premium-deal 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/enara-bio-strengthens-dark-antigen-platform-with-expanded-boehringer-partnership-and-new-cmo-ahead-of-ena101-clinical-entry 2026-01-08T18:02:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enara-bio-strengthens-dark-antigen-platform-with-expanded-boehringer-partnership-and-new-cmo-ahead-of-ena101-clinical-entry 2026-01-08T18:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/kahr-bio-s-dsp107-shows-promising-17-5-month-survival-in-advanced-colorectal-cancer-phase-2-trial 2026-01-08T18:01:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kahr-bio-s-dsp107-shows-promising-17-5-month-survival-in-advanced-colorectal-cancer-phase-2-trial 2026-01-08T18:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/alveus-therapeutics-raises-160-million-series-a-to-advance-novel-obesity-therapies 2026-01-08T18:01:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alveus-therapeutics-raises-160-million-series-a-to-advance-novel-obesity-therapies 2026-01-08T18:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-partners-with-johnson-johnson-to-advance-localized-cardiac-gene-therapy-using-impella-heart-pump-technology 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexeo-therapeutics-partners-with-johnson-johnson-to-advance-localized-cardiac-gene-therapy-using-impella-heart-pump-technology 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-advances-gene-therapy-for-stargardt-disease-with-first-patient-dosed-in-phase-1-2-expansion-trial 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splicebio-advances-gene-therapy-for-stargardt-disease-with-first-patient-dosed-in-phase-1-2-expansion-trial 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-advances-rsv-treatment-pipeline-and-expands-immunology-portfolio-with-three-novel-targets 2026-01-08T18:00:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-advances-rsv-treatment-pipeline-and-expands-immunology-portfolio-with-three-novel-targets 2026-01-08T18:00:04+00:00 hourly 0.9 https://trial.medpath.com/news/enterobiotix-s-ebx-102-02-shows-promise-as-first-in-class-oral-microbiome-therapy-for-irritable-bowel-syndrome 2026-01-08T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterobiotix-s-ebx-102-02-shows-promise-as-first-in-class-oral-microbiome-therapy-for-irritable-bowel-syndrome 2026-01-08T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/858-therapeutics-receives-fda-fast-track-designation-for-parg-inhibitor-etx-19477-in-brca-mutated-ovarian-cancer 2026-01-08T17:58:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/858-therapeutics-receives-fda-fast-track-designation-for-parg-inhibitor-etx-19477-in-brca-mutated-ovarian-cancer 2026-01-08T17:58:57+00:00 hourly 0.9 https://trial.medpath.com/news/bamf-health-and-henry-ford-health-partner-to-establish-comprehensive-theranostics-center-in-detroit 2026-01-08T17:58:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bamf-health-and-henry-ford-health-partner-to-establish-comprehensive-theranostics-center-in-detroit 2026-01-08T17:58:48+00:00 hourly 0.9 https://trial.medpath.com/news/antin-infrastructure-partners-acquires-clinical-trial-equipment-leader-emsere-in-strategic-healthcare-move 2026-01-08T17:58:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antin-infrastructure-partners-acquires-clinical-trial-equipment-leader-emsere-in-strategic-healthcare-move 2026-01-08T17:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/just-evotec-biologics-secures-gates-foundation-grant-for-ai-driven-monoclonal-antibody-optimization-to-expand-global-access 2026-01-08T13:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/just-evotec-biologics-secures-gates-foundation-grant-for-ai-driven-monoclonal-antibody-optimization-to-expand-global-access 2026-01-08T13:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/storm-therapeutics-partners-with-alidabio-to-advance-first-in-class-rna-modifying-enzyme-inhibitor-stc-15 2026-01-08T13:00:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/storm-therapeutics-partners-with-alidabio-to-advance-first-in-class-rna-modifying-enzyme-inhibitor-stc-15 2026-01-08T13:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/epibiologics-raises-107m-series-b-to-advance-novel-egfr-targeting-bispecific-antibody-epi-326-into-clinical-trials 2026-01-08T13:00:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epibiologics-raises-107m-series-b-to-advance-novel-egfr-targeting-bispecific-antibody-epi-326-into-clinical-trials 2026-01-08T13:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-to-present-phase-1-data-for-kb407-gene-therapy-in-cystic-fibrosis 2026-01-08T12:59:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/krystal-biotech-to-present-phase-1-data-for-kb407-gene-therapy-in-cystic-fibrosis 2026-01-08T12:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/hansoh-pharmaceutical-s-aumolertinib-receives-eu-approval-for-advanced-nsclc-treatment 2026-01-08T12:59:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansoh-pharmaceutical-s-aumolertinib-receives-eu-approval-for-advanced-nsclc-treatment 2026-01-08T12:59:29+00:00 hourly 0.9 https://trial.medpath.com/news/aboleris-pharma-advances-novel-anti-cd45rc-antibody-abo21009-to-patient-testing-in-rheumatoid-arthritis-phase-1-trial 2026-01-08T12:59:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aboleris-pharma-advances-novel-anti-cd45rc-antibody-abo21009-to-patient-testing-in-rheumatoid-arthritis-phase-1-trial 2026-01-08T12:59:24+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-therapeutics-in-584-5-million-deal 2026-01-08T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-therapeutics-in-584-5-million-deal 2026-01-08T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-spine-secures-two-new-u-s-patents-strengthening-spinal-implant-innovation-portfolio 2026-01-08T12:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurora-spine-secures-two-new-u-s-patents-strengthening-spinal-implant-innovation-portfolio 2026-01-08T12:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/tensive-reports-positive-pivotal-trial-results-for-regeneratm-bioresorbable-breast-reconstruction-device 2026-01-08T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tensive-reports-positive-pivotal-trial-results-for-regeneratm-bioresorbable-breast-reconstruction-device 2026-01-08T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/ligachem-bioscience-achieves-development-milestone-in-adc-platform-partnership-with-ono-pharmaceutical 2026-01-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligachem-bioscience-achieves-development-milestone-in-adc-platform-partnership-with-ono-pharmaceutical 2026-01-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/ametris-expands-digital-health-partnerships-with-major-pharmaceutical-companies 2026-01-08T10:01:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ametris-expands-digital-health-partnerships-with-major-pharmaceutical-companies 2026-01-08T10:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/pulmocide-terminates-phase-3-trial-of-inhaled-opelconazole-after-interim-analysis-shows-higher-mortality 2026-01-08T10:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmocide-terminates-phase-3-trial-of-inhaled-opelconazole-after-interim-analysis-shows-higher-mortality 2026-01-08T10:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/4moving-biotech-secures-fda-ind-clearance-for-first-in-class-intra-articular-glp-1-agonist-in-osteoarthritis 2026-01-08T09:59:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4moving-biotech-secures-fda-ind-clearance-for-first-in-class-intra-articular-glp-1-agonist-in-osteoarthritis 2026-01-08T09:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/neuralight-completes-paloma-study-demonstrating-superior-eye-movement-biomarkers-for-parkinson-s-disease-progression-tracking 2026-01-08T09:59:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralight-completes-paloma-study-demonstrating-superior-eye-movement-biomarkers-for-parkinson-s-disease-progression-tracking 2026-01-08T09:59:51+00:00 hourly 0.9 https://trial.medpath.com/news/spider-venom-derived-drug-ib409-enters-phase-1-clinical-trial-for-heart-attack-and-stroke-treatment 2026-01-08T09:59:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spider-venom-derived-drug-ib409-enters-phase-1-clinical-trial-for-heart-attack-and-stroke-treatment 2026-01-08T09:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-ogsiveo-becomes-first-approved-desmoid-tumor-treatment-in-europe 2026-01-08T09:59:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-ogsiveo-becomes-first-approved-desmoid-tumor-treatment-in-europe 2026-01-08T09:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-reports-promising-phase-1-results-for-novel-gipr-antagonist-at7687-in-obesity-treatment 2026-01-08T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antag-therapeutics-reports-promising-phase-1-results-for-novel-gipr-antagonist-at7687-in-obesity-treatment 2026-01-08T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ray-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-optogenetic-vision-therapies 2026-01-08T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ray-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-optogenetic-vision-therapies 2026-01-08T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bighat-biosciences-expands-lilly-partnership-to-develop-ai-powered-antibody-developability-models 2026-01-08T06:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bighat-biosciences-expands-lilly-partnership-to-develop-ai-powered-antibody-developability-models 2026-01-08T06:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-s-single-dose-oral-cholera-vaccine-panchol-demonstrates-safety-and-strong-immune-response-in-phase-1-trial 2026-01-08T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-s-single-dose-oral-cholera-vaccine-panchol-demonstrates-safety-and-strong-immune-response-in-phase-1-trial 2026-01-08T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/mercy-health-system-joins-major-clinical-study-testing-multi-cancer-blood-screening-in-medicare-population 2026-01-08T04:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercy-health-system-joins-major-clinical-study-testing-multi-cancer-blood-screening-in-medicare-population 2026-01-08T04:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-initiates-phase-ib-trial-of-bbt002-bispecific-antibody-for-copd-treatment 2026-01-08T04:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-initiates-phase-ib-trial-of-bbt002-bispecific-antibody-for-copd-treatment 2026-01-08T04:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/gland-pharma-receives-fda-approval-for-generic-extra-strength-pataday-eye-allergy-drops 2026-01-08T04:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gland-pharma-receives-fda-approval-for-generic-extra-strength-pataday-eye-allergy-drops 2026-01-08T04:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/corsera-health-raises-80m-series-a-as-preventative-cardiovascular-sirna-therapy-enters-clinical-testing 2026-01-08T02:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corsera-health-raises-80m-series-a-as-preventative-cardiovascular-sirna-therapy-enters-clinical-testing 2026-01-08T02:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-cognition-launches-real-world-study-for-zunveyl-as-alzheimer-s-drug-gains-commercial-traction 2026-01-08T02:24:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-cognition-launches-real-world-study-for-zunveyl-as-alzheimer-s-drug-gains-commercial-traction 2026-01-08T02:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/prudentia-sciences-raises-20m-series-a-to-transform-life-sciences-due-diligence-with-ai-platform 2026-01-08T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prudentia-sciences-raises-20m-series-a-to-transform-life-sciences-due-diligence-with-ai-platform 2026-01-08T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bacterial-vesicles-boost-car-t-cell-therapy-effectiveness-against-solid-tumors 2026-01-08T02:18:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-bacterial-vesicles-boost-car-t-cell-therapy-effectiveness-against-solid-tumors 2026-01-08T02:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/pretrm-blood-test-reduces-preterm-birth-complications-in-large-randomized-trial 2026-01-08T02:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pretrm-blood-test-reduces-preterm-birth-complications-in-large-randomized-trial 2026-01-08T02:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-s-gamifant-shows-promise-in-phase-2a-trial-for-interferon-gamma-driven-sepsis 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-s-gamifant-shows-promise-in-phase-2a-trial-for-interferon-gamma-driven-sepsis 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/ottimo-pharma-receives-fda-clearance-for-first-in-class-dual-pd-1-vegfr2-antibody-otp-01 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ottimo-pharma-receives-fda-clearance-for-first-in-class-dual-pd-1-vegfr2-antibody-otp-01 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/deepseq-ai-secures-investment-from-zaka-vc-to-advance-ai-driven-protein-drug-discovery-platform 2026-01-08T02:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepseq-ai-secures-investment-from-zaka-vc-to-advance-ai-driven-protein-drug-discovery-platform 2026-01-08T02:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/arbele-s-arb1002-receives-fda-orphan-drug-designation-for-pancreatic-cancer-treatment 2026-01-08T02:15:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arbele-s-arb1002-receives-fda-orphan-drug-designation-for-pancreatic-cancer-treatment 2026-01-08T02:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-acquires-lumabridge-to-establish-global-oncology-center-of-excellence 2026-01-08T02:15:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-acquires-lumabridge-to-establish-global-oncology-center-of-excellence 2026-01-08T02:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/elevatebio-reports-sixth-consecutive-year-of-revenue-growth-with-98-manufacturing-success-rate 2026-01-08T02:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevatebio-reports-sixth-consecutive-year-of-revenue-growth-with-98-manufacturing-success-rate 2026-01-08T02:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-reduce-asthma-exacerbations-by-49-in-adolescents-with-obesity 2026-01-08T02:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-reduce-asthma-exacerbations-by-49-in-adolescents-with-obesity 2026-01-08T02:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-ottava-robotic-surgical-system-to-fda-for-de-novo-classification 2026-01-08T02:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-submits-ottava-robotic-surgical-system-to-fda-for-de-novo-classification 2026-01-08T02:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-initiates-phase-3-trial-for-vp-102-in-common-warts-treatment 2026-01-08T02:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-initiates-phase-3-trial-for-vp-102-in-common-warts-treatment 2026-01-08T02:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/varsity-healthcare-partners-invests-in-trialbee-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varsity-healthcare-partners-invests-in-trialbee-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/trialbee-secures-majority-investment-from-varsity-healthcare-partners-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trialbee-secures-majority-investment-from-varsity-healthcare-partners-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-companies-seek-direct-deals-with-trump-administration-to-avoid-pricing-penalties 2026-01-08T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-companies-seek-direct-deals-with-trump-administration-to-avoid-pricing-penalties 2026-01-08T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/volastra-therapeutics-expands-kif18a-inhibitor-program-following-positive-clinical-data 2026-01-08T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volastra-therapeutics-expands-kif18a-inhibitor-program-following-positive-clinical-data 2026-01-08T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/ovation-science-secures-canadian-patent-for-enhanced-cannabinoid-transdermal-delivery-technology 2026-01-08T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovation-science-secures-canadian-patent-for-enhanced-cannabinoid-transdermal-delivery-technology 2026-01-08T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-svn-15-matches-prozac-efficacy-in-depression-model-targets-dual-serotonin-dopamine-pathway 2026-01-08T02:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solvonis-therapeutics-svn-15-matches-prozac-efficacy-in-depression-model-targets-dual-serotonin-dopamine-pathway 2026-01-08T02:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-appoints-new-ceo-as-company-prepares-for-phase-1-trial-of-novel-neutrophil-based-cancer-immunotherapy 2026-01-08T02:05:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lift-biosciences-appoints-new-ceo-as-company-prepares-for-phase-1-trial-of-novel-neutrophil-based-cancer-immunotherapy 2026-01-08T02:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/luminate-secures-21-million-series-a-to-advance-home-based-cancer-treatment-technology 2026-01-08T02:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luminate-secures-21-million-series-a-to-advance-home-based-cancer-treatment-technology 2026-01-08T02:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-s-mrt-8102-demonstrates-85-reduction-in-cardiovascular-inflammation-marker-in-phase-1-trial 2026-01-08T02:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-s-mrt-8102-demonstrates-85-reduction-in-cardiovascular-inflammation-marker-in-phase-1-trial 2026-01-08T02:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-secures-76-million-series-b-to-advance-first-in-class-anti-fibrotic-pipeline 2026-01-08T02:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediar-therapeutics-secures-76-million-series-b-to-advance-first-in-class-anti-fibrotic-pipeline 2026-01-08T02:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/inimmune-launches-pivotal-phase-2-trial-of-ini-2004-for-allergic-rhinitis-treatment 2026-01-08T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inimmune-launches-pivotal-phase-2-trial-of-ini-2004-for-allergic-rhinitis-treatment 2026-01-08T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/curium-receives-chinese-regulatory-approval-to-begin-phase-3-trial-of-177lu-psma-i-t-for-metastatic-prostate-cancer 2026-01-08T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curium-receives-chinese-regulatory-approval-to-begin-phase-3-trial-of-177lu-psma-i-t-for-metastatic-prostate-cancer 2026-01-08T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/adicet-bio-advances-gamma-delta-t-cell-therapy-pipeline-with-fda-alignment-and-2026-milestones 2026-01-08T02:00:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adicet-bio-advances-gamma-delta-t-cell-therapy-pipeline-with-fda-alignment-and-2026-milestones 2026-01-08T02:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-rebrands-as-kyntra-bio-advances-cd46-targeting-adc-and-roxadustat-programs 2026-01-08T02:00:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrogen-rebrands-as-kyntra-bio-advances-cd46-targeting-adc-and-roxadustat-programs 2026-01-08T02:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-grant-orphan-drug-designation-to-cpi-008-for-pancreatic-cancer-surgical-imaging 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-ema-grant-orphan-drug-designation-to-cpi-008-for-pancreatic-cancer-surgical-imaging 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/realta-life-sciences-appoints-biotech-veteran-jonathan-rigby-to-board-as-company-advances-inflammation-targeting-pipeline 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/realta-life-sciences-appoints-biotech-veteran-jonathan-rigby-to-board-as-company-advances-inflammation-targeting-pipeline 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-completes-phase-3-enrollment-for-multiple-sclerosis-drug-reports-positive-progressive-ms-data 2026-01-08T01:59:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-completes-phase-3-enrollment-for-multiple-sclerosis-drug-reports-positive-progressive-ms-data 2026-01-08T01:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-and-unravel-biosciences-partner-to-develop-first-in-class-remyelination-therapy-for-multiple-sclerosis 2026-01-08T01:59:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-and-unravel-biosciences-partner-to-develop-first-in-class-remyelination-therapy-for-multiple-sclerosis 2026-01-08T01:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/headlamp-health-launches-lumos-ai-platform-to-transform-neuroscience-drug-development 2026-01-08T01:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/headlamp-health-launches-lumos-ai-platform-to-transform-neuroscience-drug-development 2026-01-08T01:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-phase-3-kandlelit-007-trial-for-calderasib-keytruda-qlex-combination-in-kras-g12c-mutant-lung-cancer 2026-01-08T01:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-launches-phase-3-kandlelit-007-trial-for-calderasib-keytruda-qlex-combination-in-kras-g12c-mutant-lung-cancer 2026-01-08T01:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-helix-in-multi-year-precision-medicine-collaboration-to-accelerate-drug-development 2026-01-08T01:59:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-partners-with-helix-in-multi-year-precision-medicine-collaboration-to-accelerate-drug-development 2026-01-08T01:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-comp360-psilocybin-ind-application-for-ptsd-treatment-as-compass-pathways-advances-late-stage-clinical-development 2026-01-08T01:57:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-comp360-psilocybin-ind-application-for-ptsd-treatment-as-compass-pathways-advances-late-stage-clinical-development 2026-01-08T01:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-secures-100-million-series-f-to-advance-asp-1929-toward-u-s-approval 2026-01-08T01:57:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakuten-medical-secures-100-million-series-f-to-advance-asp-1929-toward-u-s-approval 2026-01-08T01:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-to-submit-snda-for-at-home-use-of-igalmi-in-agitation-treatment 2026-01-08T01:57:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-to-submit-snda-for-at-home-use-of-igalmi-in-agitation-treatment 2026-01-08T01:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-and-10x-genomics-launch-immunescape-program-to-decode-transplant-rejection-using-multiomics-technology 2026-01-08T01:57:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-and-10x-genomics-launch-immunescape-program-to-decode-transplant-rejection-using-multiomics-technology 2026-01-08T01:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-partners-with-woda-to-expand-global-access-to-revuforj-through-multi-regional-managed-access-program 2026-01-08T01:57:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-partners-with-woda-to-expand-global-access-to-revuforj-through-multi-regional-managed-access-program 2026-01-08T01:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/silybin-carvedilol-combination-shows-synergistic-effects-against-liver-fibrosis-in-preclinical-studies 2026-01-08T01:57:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silybin-carvedilol-combination-shows-synergistic-effects-against-liver-fibrosis-in-preclinical-studies 2026-01-08T01:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-acquires-entomon-to-strengthen-venom-immunotherapy-supply-chain 2026-01-08T01:55:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stallergenes-greer-acquires-entomon-to-strengthen-venom-immunotherapy-supply-chain 2026-01-08T01:55:41+00:00 hourly 0.9 https://trial.medpath.com/news/scenic-biotech-partners-with-ono-pharmaceutical-to-advance-novel-target-discovery-using-cell-seq-platform 2026-01-08T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scenic-biotech-partners-with-ono-pharmaceutical-to-advance-novel-target-discovery-using-cell-seq-platform 2026-01-08T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-bepirovirsen-achieves-breakthrough-functional-cure-rates-in-phase-iii-chronic-hepatitis-b-trials 2026-01-08T01:52:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-bepirovirsen-achieves-breakthrough-functional-cure-rates-in-phase-iii-chronic-hepatitis-b-trials 2026-01-08T01:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/neurosterix-initiates-phase-1-trial-of-ntx-253-novel-m4-receptor-modulator-for-schizophrenia-treatment 2026-01-08T01:51:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosterix-initiates-phase-1-trial-of-ntx-253-novel-m4-receptor-modulator-for-schizophrenia-treatment 2026-01-08T01:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-experimental-hepatitis-b-drug-bepirovirsen-achieves-functional-cure-in-pivotal-studies 2026-01-08T01:51:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-experimental-hepatitis-b-drug-bepirovirsen-achieves-functional-cure-in-pivotal-studies 2026-01-08T01:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/jjp-biologics-reports-positive-phase-i-results-for-first-in-class-anti-cd89-antibody-jjp-1212 2026-01-08T01:51:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jjp-biologics-reports-positive-phase-i-results-for-first-in-class-anti-cd89-antibody-jjp-1212 2026-01-08T01:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/merck-pursues-acquisition-of-cancer-drug-developer-revolution-medicines 2026-01-08T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-pursues-acquisition-of-cancer-drug-developer-revolution-medicines 2026-01-08T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/cvrx-launches-benefit-hf-trial-to-evaluate-barostim-therapy-in-expanded-heart-failure-population 2026-01-08T01:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvrx-launches-benefit-hf-trial-to-evaluate-barostim-therapy-in-expanded-heart-failure-population 2026-01-08T01:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-receives-fda-clearance-for-novel-btk-protein-degrader-apg-3288-in-b-cell-malignancies 2026-01-08T01:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-receives-fda-clearance-for-novel-btk-protein-degrader-apg-3288-in-b-cell-malignancies 2026-01-08T01:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/arcutis-projects-455-470m-zoryve-revenue-for-2026-as-dermatology-portfolio-expands 2026-01-08T01:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcutis-projects-455-470m-zoryve-revenue-for-2026-as-dermatology-portfolio-expands 2026-01-08T01:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-sovleplenib-meets-primary-endpoint-in-phase-iii-trial-for-warm-autoimmune-hemolytic-anemia 2026-01-08T01:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-s-sovleplenib-meets-primary-endpoint-in-phase-iii-trial-for-warm-autoimmune-hemolytic-anemia 2026-01-08T01:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/healthbiome-achieves-dual-regulatory-approval-for-akkermansia-based-muscle-health-ingredient 2026-01-08T01:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthbiome-achieves-dual-regulatory-approval-for-akkermansia-based-muscle-health-ingredient 2026-01-08T01:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-sues-major-covid-19-vaccine-makers-over-alleged-mrna-technology-patent-infringement 2026-01-08T01:44:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-sues-major-covid-19-vaccine-makers-over-alleged-mrna-technology-patent-infringement 2026-01-08T01:44:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-expands-genetic-medicine-portfolio-through-strategic-sirna-and-ai-partnerships 2026-01-08T01:44:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-expands-genetic-medicine-portfolio-through-strategic-sirna-and-ai-partnerships 2026-01-08T01:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/picard-medical-launches-fda-cleared-connector-covers-for-syncardia-total-artificial-heart 2026-01-08T01:44:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/picard-medical-launches-fda-cleared-connector-covers-for-syncardia-total-artificial-heart 2026-01-08T01:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/nucana-appoints-theresa-bruce-as-coo-to-advance-cancer-drug-pipeline 2026-01-08T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucana-appoints-theresa-bruce-as-coo-to-advance-cancer-drug-pipeline 2026-01-08T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/dem-biopharma-to-present-first-in-class-adc-dem301-for-gastrointestinal-cancers-at-asco-gi-2026 2026-01-08T01:43:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dem-biopharma-to-present-first-in-class-adc-dem301-for-gastrointestinal-cancers-at-asco-gi-2026 2026-01-08T01:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-parkinson-s-therapies-advance-to-late-stage-clinical-trials 2026-01-08T01:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-novel-parkinson-s-therapies-advance-to-late-stage-clinical-trials 2026-01-08T01:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-terminates-licensing-agreement-and-discontinues-lead-cancer-drug-development 2026-01-08T01:41:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/instil-bio-terminates-licensing-agreement-and-discontinues-lead-cancer-drug-development 2026-01-08T01:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/exvade-bioscience-enrolls-first-patients-in-revolutionary-glioblastoma-trial-using-fda-breakthrough-tumor-monorail-device 2026-01-08T01:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exvade-bioscience-enrolls-first-patients-in-revolutionary-glioblastoma-trial-using-fda-breakthrough-tumor-monorail-device 2026-01-08T01:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-initiates-phase-2b-trial-of-clofutriben-for-difficult-to-control-type-2-diabetes 2026-01-08T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparrow-pharmaceuticals-initiates-phase-2b-trial-of-clofutriben-for-difficult-to-control-type-2-diabetes 2026-01-08T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/mdxhealth-partners-with-oxford-to-validate-genomic-prostate-score-in-landmark-protect-trial 2026-01-08T01:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mdxhealth-partners-with-oxford-to-validate-genomic-prostate-score-in-landmark-protect-trial 2026-01-08T01:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cuts-childhood-vaccine-schedule-from-17-to-11-diseases-impacting-major-vaccine-manufacturers 2026-01-08T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-cuts-childhood-vaccine-schedule-from-17-to-11-diseases-impacting-major-vaccine-manufacturers 2026-01-08T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/novoron-bioscience-secures-2-5m-nih-grant-to-advance-human-brain-organoid-platform-for-alzheimer-s-drug-discovery 2026-01-08T01:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novoron-bioscience-secures-2-5m-nih-grant-to-advance-human-brain-organoid-platform-for-alzheimer-s-drug-discovery 2026-01-08T01:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-receives-fda-clearance-to-advance-botanical-drug-cinainu-into-phase-3-trial-for-alopecia-areata 2026-01-08T01:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legacy-healthcare-receives-fda-clearance-to-advance-botanical-drug-cinainu-into-phase-3-trial-for-alopecia-areata 2026-01-08T01:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-biotech-receives-fda-approval-for-streamlined-vvn461hd-development-path-in-non-infectious-anterior-uveitis 2026-01-08T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivavision-biotech-receives-fda-approval-for-streamlined-vvn461hd-development-path-in-non-infectious-anterior-uveitis 2026-01-08T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/baird-medical-expands-global-microwave-ablation-technology-footprint-with-new-market-launches 2026-01-07T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baird-medical-expands-global-microwave-ablation-technology-footprint-with-new-market-launches 2026-01-07T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/alloy-therapeutics-names-christian-cobaugh-ceo-of-genetic-medicines-division-to-advance-anticlastic-rna-platform 2026-01-07T09:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alloy-therapeutics-names-christian-cobaugh-ceo-of-genetic-medicines-division-to-advance-anticlastic-rna-platform 2026-01-07T09:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-gene-silencing-drugs-show-promise-in-early-obesity-studies-enhancing-weight-loss-when-combined-with-zepbound 2026-01-07T09:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-s-gene-silencing-drugs-show-promise-in-early-obesity-studies-enhancing-weight-loss-when-combined-with-zepbound 2026-01-07T09:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-publishes-mechanism-data-for-vowst-in-nature-medicine-validates-live-biotherapeutics-platform 2026-01-07T09:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seres-therapeutics-publishes-mechanism-data-for-vowst-in-nature-medicine-validates-live-biotherapeutics-platform 2026-01-07T09:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/three-biotech-companies-secure-international-funding-for-next-generation-genetic-medicine-platform 2026-01-07T09:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-biotech-companies-secure-international-funding-for-next-generation-genetic-medicine-platform 2026-01-07T09:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-up-to-840-million-to-advance-acute-leukemia-pipeline 2026-01-07T09:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-acquires-dark-blue-therapeutics-for-up-to-840-million-to-advance-acute-leukemia-pipeline 2026-01-07T09:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-secures-patent-license-for-obesity-drug-ct-996-in-100-million-deal-with-structure-therapeutics 2026-01-07T09:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-secures-patent-license-for-obesity-drug-ct-996-in-100-million-deal-with-structure-therapeutics 2026-01-07T09:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/3t-biosciences-strengthens-leadership-with-key-appointments-to-advance-solid-tumor-immunotherapy-pipeline 2026-01-07T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3t-biosciences-strengthens-leadership-with-key-appointments-to-advance-solid-tumor-immunotherapy-pipeline 2026-01-07T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/kincell-bio-appoints-industry-veteran-larry-pitcher-as-ceo-to-drive-cell-therapy-manufacturing-expansion 2026-01-07T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kincell-bio-appoints-industry-veteran-larry-pitcher-as-ceo-to-drive-cell-therapy-manufacturing-expansion 2026-01-07T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/aclaris-therapeutics-reports-positive-phase-1a-results-for-bispecific-antibody-ati-052-accelerating-development-timeline 2026-01-07T09:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclaris-therapeutics-reports-positive-phase-1a-results-for-bispecific-antibody-ati-052-accelerating-development-timeline 2026-01-07T09:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/ibex-medical-analytics-expands-ai-powered-pathology-platform-to-support-early-stage-drug-development 2026-01-07T09:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibex-medical-analytics-expands-ai-powered-pathology-platform-to-support-early-stage-drug-development 2026-01-07T09:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/pridcor-therapeutics-advances-long-covid-treatment-with-peer-reviewed-publication-and-fda-ind-exemption-for-phase-2-shield-study 2026-01-07T09:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pridcor-therapeutics-advances-long-covid-treatment-with-peer-reviewed-publication-and-fda-ind-exemption-for-phase-2-shield-study 2026-01-07T09:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/bactolife-raises-eur30-million-series-b-to-commercialize-gut-health-binding-proteins-technology 2026-01-07T09:28:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bactolife-raises-eur30-million-series-b-to-commercialize-gut-health-binding-proteins-technology 2026-01-07T09:28:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-maviret-as-first-eight-week-treatment-for-acute-hepatitis-c 2026-01-07T09:28:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-maviret-as-first-eight-week-treatment-for-acute-hepatitis-c 2026-01-07T09:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-skin-derived-paste-shows-promise-for-breast-reconstruction-after-cancer-surgery 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-skin-derived-paste-shows-promise-for-breast-reconstruction-after-cancer-surgery 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-s-dna-therapy-eg110a-maintains-88-reduction-in-neurogenic-bladder-incontinence-at-24-weeks 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eg-427-s-dna-therapy-eg110a-maintains-88-reduction-in-neurogenic-bladder-incontinence-at-24-weeks 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-announces-ceo-succession-as-lisa-graver-takes-leadership-of-biosimilar-company 2026-01-07T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-announces-ceo-succession-as-lisa-graver-takes-leadership-of-biosimilar-company 2026-01-07T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-nipocalimab-achieves-first-positive-phase-2-results-for-systemic-lupus-erythematosus-treatment 2026-01-07T09:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-nipocalimab-achieves-first-positive-phase-2-results-for-systemic-lupus-erythematosus-treatment 2026-01-07T09:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-s-gene-therapy-gpx-002-shows-promise-in-type-2-diabetes-animal-studies 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genprex-s-gene-therapy-gpx-002-shows-promise-in-type-2-diabetes-animal-studies 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-advances-first-fda-approved-mitochondrial-therapy-forzinity-for-barth-syndrome 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stealth-biotherapeutics-advances-first-fda-approved-mitochondrial-therapy-forzinity-for-barth-syndrome 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomendics-advances-first-in-class-therapy-for-epidermolysis-bullosa-simplex-with-tames-02-trial 2026-01-07T09:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomendics-advances-first-in-class-therapy-for-epidermolysis-bullosa-simplex-with-tames-02-trial 2026-01-07T09:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-advances-azenosertib-toward-potential-accelerated-approval-with-key-2026-milestones-in-ovarian-cancer 2026-01-07T09:27:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-advances-azenosertib-toward-potential-accelerated-approval-with-key-2026-milestones-in-ovarian-cancer 2026-01-07T09:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-strengthens-leadership-team-with-blueprint-medicines-veterans-as-dmr-001-advances-toward-clinical-trials 2026-01-07T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galecto-strengthens-leadership-team-with-blueprint-medicines-veterans-as-dmr-001-advances-toward-clinical-trials 2026-01-07T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-partners-with-onconano-medicine-in-300m-drug-delivery-collaboration-for-cancer-therapeutics 2026-01-07T09:26:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-partners-with-onconano-medicine-in-300m-drug-delivery-collaboration-for-cancer-therapeutics 2026-01-07T09:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-s-wrn-inhibitor-vvd-214-shows-promise-for-msi-high-cancers-in-journal-of-medicinal-chemistry-publication 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vividion-s-wrn-inhibitor-vvd-214-shows-promise-for-msi-high-cancers-in-journal-of-medicinal-chemistry-publication 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-and-astrazeneca-partner-to-deploy-ai-foundation-model-for-precision-oncology-development 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-and-astrazeneca-partner-to-deploy-ai-foundation-model-for-precision-oncology-development 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/regentis-gelrinc-demonstrates-near-complete-cartilage-repair-in-24-month-phase-ii-study-using-quantitative-mocart-assessment 2026-01-07T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regentis-gelrinc-demonstrates-near-complete-cartilage-repair-in-24-month-phase-ii-study-using-quantitative-mocart-assessment 2026-01-07T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-initiates-phase-2-trial-of-praliciguat-for-rare-kidney-disease-fsgs 2026-01-07T09:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-therapeutics-initiates-phase-2-trial-of-praliciguat-for-rare-kidney-disease-fsgs 2026-01-07T09:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-study-reveals-one-third-of-clinical-trial-procedures-are-non-essential-proposes-streamlined-data-collection-framework 2026-01-07T09:26:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcelerate-study-reveals-one-third-of-clinical-trial-procedures-are-non-essential-proposes-streamlined-data-collection-framework 2026-01-07T09:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-venous-stent-for-deep-venous-disease-in-ivc-and-iliofemoral-veins 2026-01-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-venous-stent-for-deep-venous-disease-in-ivc-and-iliofemoral-veins 2026-01-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/loqus23-advances-first-in-class-oral-drug-lqt-23-for-huntington-s-disease-treatment 2026-01-07T09:26:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loqus23-advances-first-in-class-oral-drug-lqt-23-for-huntington-s-disease-treatment 2026-01-07T09:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-s-northstar-select-liquid-biopsy-selected-for-major-japanese-lung-cancer-resistance-study 2026-01-07T09:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/billiontoone-s-northstar-select-liquid-biopsy-selected-for-major-japanese-lung-cancer-resistance-study 2026-01-07T09:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-840-million-to-advance-aml-treatment 2026-01-07T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-acquires-dark-blue-therapeutics-for-840-million-to-advance-aml-treatment 2026-01-07T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-italy-consortium-launches-ps3m-study-to-define-true-remission-in-inflammatory-arthritis 2026-01-07T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-italy-consortium-launches-ps3m-study-to-define-true-remission-in-inflammatory-arthritis 2026-01-07T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/variant-bio-launches-world-s-first-agentic-ai-platform-for-genomic-drug-discovery 2026-01-07T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/variant-bio-launches-world-s-first-agentic-ai-platform-for-genomic-drug-discovery 2026-01-07T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-initiates-phase-1-trial-of-novel-mrna-hiv-vaccine-targeting-broadly-neutralizing-antibodies 2026-01-07T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iavi-initiates-phase-1-trial-of-novel-mrna-hiv-vaccine-targeting-broadly-neutralizing-antibodies 2026-01-07T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/nanomosaic-appoints-dr-anne-marie-morse-to-lead-clinical-advisory-board-for-ultra-sensitive-diagnostic-platform 2026-01-07T09:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanomosaic-appoints-dr-anne-marie-morse-to-lead-clinical-advisory-board-for-ultra-sensitive-diagnostic-platform 2026-01-07T09:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/biosplice-submits-first-potential-disease-modifying-osteoarthritis-drug-to-fda 2026-01-07T09:24:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosplice-submits-first-potential-disease-modifying-osteoarthritis-drug-to-fda 2026-01-07T09:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/aclarion-advances-clarity-trial-enrollment-with-northwestern-medicine-and-scripps-health-participation 2026-01-07T09:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclarion-advances-clarity-trial-enrollment-with-northwestern-medicine-and-scripps-health-participation 2026-01-07T09:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-s-zumilokibart-shows-promising-results-in-phase-1b-asthma-trial-with-durable-biomarker-suppression 2026-01-07T09:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-s-zumilokibart-shows-promising-results-in-phase-1b-asthma-trial-with-durable-biomarker-suppression 2026-01-07T09:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/cyclerion-therapeutics-partners-with-medsteer-to-advance-cyc-126-for-treatment-resistant-depression 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclerion-therapeutics-partners-with-medsteer-to-advance-cyc-126-for-treatment-resistant-depression 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/leon-s-fr-jet-technology-enables-high-concentration-mrna-lnp-manufacturing-with-enhanced-in-vivo-activity 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leon-s-fr-jet-technology-enables-high-concentration-mrna-lnp-manufacturing-with-enhanced-in-vivo-activity 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-initiates-european-enrollment-for-fortify-trial-testing-orticumab-in-post-heart-attack-inflammation 2026-01-07T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-initiates-european-enrollment-for-fortify-trial-testing-orticumab-in-post-heart-attack-inflammation 2026-01-07T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/hummingbird-bioscience-doses-first-patient-in-phase-i-trial-of-her3-targeted-adc-hmbd-501 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hummingbird-bioscience-doses-first-patient-in-phase-i-trial-of-her3-targeted-adc-hmbd-501 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/acesion-pharma-initiates-phase-2-trial-of-first-in-class-sk-ion-channel-inhibitor-ap31969-for-atrial-fibrillation 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acesion-pharma-initiates-phase-2-trial-of-first-in-class-sk-ion-channel-inhibitor-ap31969-for-atrial-fibrillation 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/ikarovec-secures-exclusive-option-for-vectorbuilder-s-novel-aav-capsid-technology-in-1b-deal-for-amd-gene-therapy 2026-01-07T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ikarovec-secures-exclusive-option-for-vectorbuilder-s-novel-aav-capsid-technology-in-1b-deal-for-amd-gene-therapy 2026-01-07T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-expands-global-clinical-trial-network-through-strategic-partnerships-with-opis-and-medicover 2026-01-07T06:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gccl-expands-global-clinical-trial-network-through-strategic-partnerships-with-opis-and-medicover 2026-01-07T06:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-expands-ultrasensitive-pathlight-mrd-test-to-colorectal-cancer-following-strong-citcca-study-results 2026-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saga-diagnostics-expands-ultrasensitive-pathlight-mrd-test-to-colorectal-cancer-following-strong-citcca-study-results 2026-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/waters-corporation-shareholders-approve-17-5-billion-merger-with-bd-biosciences-transaction-set-to-close-february-2026 2026-01-06T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-corporation-shareholders-approve-17-5-billion-merger-with-bd-biosciences-transaction-set-to-close-february-2026 2026-01-06T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-azstarys-for-adhd-treatment-offering-first-dual-mechanism-therapy-for-23-million-affected-patients 2026-01-06T10:00:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-azstarys-for-adhd-treatment-offering-first-dual-mechanism-therapy-for-23-million-affected-patients 2026-01-06T10:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-set-to-release-phase-2-results-for-bmb-101-in-drug-resistant-epilepsy 2026-01-06T10:00:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-set-to-release-phase-2-results-for-bmb-101-in-drug-resistant-epilepsy 2026-01-06T10:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-first-human-dosing-milestone-for-novel-cns-inhalation-therapy 2026-01-06T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-achieves-first-human-dosing-milestone-for-novel-cns-inhalation-therapy 2026-01-06T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-bacteria-derived-molecule-doubles-lung-cancer-immunotherapy-response-in-preclinical-study 2026-01-06T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-bacteria-derived-molecule-doubles-lung-cancer-immunotherapy-response-in-preclinical-study 2026-01-06T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/sisram-medical-s-daxxify-clears-final-regulatory-hurdle-for-china-market-launch 2026-01-06T03:19:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sisram-medical-s-daxxify-clears-final-regulatory-hurdle-for-china-market-launch 2026-01-06T03:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-to-report-phase-3-onward-topline-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis 2026-01-06T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alumis-to-report-phase-3-onward-topline-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis 2026-01-06T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapy-gains-momentum-with-four-new-clinical-programs-entering-phase-1-studies 2026-01-06T00:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-vivo-car-t-therapy-gains-momentum-with-four-new-clinical-programs-entering-phase-1-studies 2026-01-06T00:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-raises-700-million-to-advance-rnai-therapeutics-pipeline 2026-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-raises-700-million-to-advance-rnai-therapeutics-pipeline 2026-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indiana-attorney-general-sues-eli-lilly-over-alleged-insulin-price-manipulation 2026-01-05T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indiana-attorney-general-sues-eli-lilly-over-alleged-insulin-price-manipulation 2026-01-05T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/decipher-genomic-classifier-shows-promise-for-predicting-prostate-cancer-treatment-outcomes 2026-01-05T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decipher-genomic-classifier-shows-promise-for-predicting-prostate-cancer-treatment-outcomes 2026-01-05T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q4-revenue-growth-of-28-driven-by-jakafi-and-opzelura-performance 2026-01-05T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-reports-strong-q4-revenue-growth-of-28-driven-by-jakafi-and-opzelura-performance 2026-01-05T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-reports-promising-early-results-for-olvi-vec-in-advanced-lung-cancer-trials 2026-01-05T20:19:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genelux-reports-promising-early-results-for-olvi-vec-in-advanced-lung-cancer-trials 2026-01-05T20:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-developed-silica-nanoparticles-transform-cold-tumors-to-enhance-immunotherapy-response 2026-01-05T20:16:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cornell-developed-silica-nanoparticles-transform-cold-tumors-to-enhance-immunotherapy-response 2026-01-05T20:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/halozyme-expands-enhanze-technology-through-strategic-partnerships-with-takeda-and-skye-bioscience 2026-01-05T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halozyme-expands-enhanze-technology-through-strategic-partnerships-with-takeda-and-skye-bioscience 2026-01-05T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-and-neurocare-group-partner-to-create-nationwide-neuroplastic-therapy-network-for-depression-and-ptsd 2026-01-05T17:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-and-neurocare-group-partner-to-create-nationwide-neuroplastic-therapy-network-for-depression-and-ptsd 2026-01-05T17:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-nmra-511-shows-clinically-meaningful-results-in-phase-1b-alzheimer-s-agitation-study 2026-01-05T17:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-s-nmra-511-shows-clinically-meaningful-results-in-phase-1b-alzheimer-s-agitation-study 2026-01-05T17:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-names-new-ceo-as-vopimetostat-advances-to-pivotal-studies 2026-01-05T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tango-therapeutics-names-new-ceo-as-vopimetostat-advances-to-pivotal-studies 2026-01-05T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-oncology-publishes-promising-data-on-ccr8-targeting-antibody-tagmokitug-for-solid-tumors 2026-01-05T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-oncology-publishes-promising-data-on-ccr8-targeting-antibody-tagmokitug-for-solid-tumors 2026-01-05T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-analysis-identifies-two-new-multiple-sclerosis-subtypes-advancing-precision-medicine-approaches 2026-01-05T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-analysis-identifies-two-new-multiple-sclerosis-subtypes-advancing-precision-medicine-approaches 2026-01-05T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/major-leucovorin-autism-study-retracted-due-to-data-issues-as-largest-trial-approaches-2026-results 2026-01-05T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-leucovorin-autism-study-retracted-due-to-data-issues-as-largest-trial-approaches-2026-results 2026-01-05T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/multi-antigen-t-cell-therapy-shows-84-6-disease-control-rate-in-pancreatic-cancer-phase-1-2-trial 2026-01-05T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-antigen-t-cell-therapy-shows-84-6-disease-control-rate-in-pancreatic-cancer-phase-1-2-trial 2026-01-05T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-ceo-to-advance-neuropathic-corneal-pain-treatment 2026-01-05T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-ceo-to-advance-neuropathic-corneal-pain-treatment 2026-01-05T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-publishes-pivotal-vykat-xr-study-results-in-leading-endocrinology-journal 2026-01-05T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soleno-therapeutics-publishes-pivotal-vykat-xr-study-results-in-leading-endocrinology-journal 2026-01-05T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-insulin-biosimilar-and-ustekinumab-alternative-in-us-market 2026-01-05T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/civicascript-launches-low-cost-insulin-biosimilar-and-ustekinumab-alternative-in-us-market 2026-01-05T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-outlines-2026-pipeline-strategy-with-multiple-clinical-readouts-expected 2026-01-05T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-therapeutics-outlines-2026-pipeline-strategy-with-multiple-clinical-readouts-expected 2026-01-05T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-therapeutics-advances-optogenetic-therapy-with-rolling-bla-submission-and-expansion-plans 2026-01-05T17:20:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-therapeutics-advances-optogenetic-therapy-with-rolling-bla-submission-and-expansion-plans 2026-01-05T17:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-strengthens-leadership-team-with-experienced-oncology-executives 2026-01-05T17:20:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-strengthens-leadership-team-with-experienced-oncology-executives 2026-01-05T17:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/nanjing-delova-s-qp-6211-achieves-primary-endpoints-in-phase-3-trials-for-postoperative-pain-management 2026-01-05T17:19:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanjing-delova-s-qp-6211-achieves-primary-endpoints-in-phase-3-trials-for-postoperative-pain-management 2026-01-05T17:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/bd-achieves-first-prophylactic-hernia-prevention-case-in-europe-with-phasix-mesh-as-prevent-trial-nears-completion 2026-01-05T17:19:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-achieves-first-prophylactic-hernia-prevention-case-in-europe-with-phasix-mesh-as-prevent-trial-nears-completion 2026-01-05T17:19:37+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-anxiety-medications-advance-toward-2026-fda-review-marking-first-major-breakthrough-in-over-a-decade 2026-01-05T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-novel-anxiety-medications-advance-toward-2026-fda-review-marking-first-major-breakthrough-in-over-a-decade 2026-01-05T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-advances-rhb-102-for-glp-1-therapy-side-effects-as-market-faces-35-billion-loss-risk 2026-01-05T16:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-advances-rhb-102-for-glp-1-therapy-side-effects-as-market-faces-35-billion-loss-risk 2026-01-05T16:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/angitia-biopharmaceuticals-completes-enrollment-in-phase-2-trial-of-dual-target-osteoporosis-therapy-aga2118 2026-01-05T16:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angitia-biopharmaceuticals-completes-enrollment-in-phase-2-trial-of-dual-target-osteoporosis-therapy-aga2118 2026-01-05T16:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-and-fast-track-designations-to-protara-s-tara-002-for-pediatric-lymphatic-malformations 2026-01-05T16:20:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-and-fast-track-designations-to-protara-s-tara-002-for-pediatric-lymphatic-malformations 2026-01-05T16:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-secures-conditional-approval-pathway-for-hydronidone-in-china-following-successful-phase-3-trial 2026-01-05T16:20:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyre-therapeutics-secures-conditional-approval-pathway-for-hydronidone-in-china-following-successful-phase-3-trial 2026-01-05T16:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/maplight-therapeutics-receives-fda-fast-track-designation-for-alzheimer-s-disease-psychosis-treatment 2026-01-05T16:19:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maplight-therapeutics-receives-fda-fast-track-designation-for-alzheimer-s-disease-psychosis-treatment 2026-01-05T16:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-reveals-1221-precision-medicine-deals-worth-billions-since-2019 2026-01-05T16:19:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-analysis-reveals-1221-precision-medicine-deals-worth-billions-since-2019 2026-01-05T16:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/stimlabs-launches-first-fda-cleared-human-umbilical-cord-particulate-device-for-wound-management 2026-01-05T16:18:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stimlabs-launches-first-fda-cleared-human-umbilical-cord-particulate-device-for-wound-management 2026-01-05T16:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/synusight-abli-therapeutics-and-xingimaging-partner-to-advance-alpha-synuclein-pet-imaging-in-parkinson-s-disease-trials 2026-01-05T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synusight-abli-therapeutics-and-xingimaging-partner-to-advance-alpha-synuclein-pet-imaging-in-parkinson-s-disease-trials 2026-01-05T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1726-demonstrates-9-1-weight-loss-and-significant-metabolic-benefits-in-phase-1b-obesity-trial 2026-01-05T16:18:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metavia-s-da-1726-demonstrates-9-1-weight-loss-and-significant-metabolic-benefits-in-phase-1b-obesity-trial 2026-01-05T16:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-pergolide-tablets-for-equine-cushing-disease-treatment 2026-01-05T16:18:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-pergolide-tablets-for-equine-cushing-disease-treatment 2026-01-05T16:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-advances-three-monoclonal-antibody-programs-for-autoimmune-diseases-with-phase-1-data-expected-in-2026 2026-01-05T13:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jade-biosciences-advances-three-monoclonal-antibody-programs-for-autoimmune-diseases-with-phase-1-data-expected-in-2026 2026-01-05T13:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-announces-leadership-transition-as-karen-massey-set-to-replace-tim-van-hauwermeiren-as-ceo 2026-01-05T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-announces-leadership-transition-as-karen-massey-set-to-replace-tim-van-hauwermeiren-as-ceo 2026-01-05T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-multiple-bispecific-antibody-programs-with-key-biliary-tract-cancer-data-expected-q1-2026 2026-01-05T13:18:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-advances-multiple-bispecific-antibody-programs-with-key-biliary-tract-cancer-data-expected-q1-2026 2026-01-05T13:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/oral-htt-lowering-drug-branaplam-shows-promise-but-halted-due-to-peripheral-neuropathy-in-phase-2-huntington-s-disease-trial 2026-01-05T13:18:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-htt-lowering-drug-branaplam-shows-promise-but-halted-due-to-peripheral-neuropathy-in-phase-2-huntington-s-disease-trial 2026-01-05T13:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/megestrol-acetate-shows-dual-benefits-in-er-positive-breast-cancer-treatment 2026-01-05T13:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/megestrol-acetate-shows-dual-benefits-in-er-positive-breast-cancer-treatment 2026-01-05T13:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/earendil-labs-partners-with-sanofi-in-2-56-billion-ai-driven-bispecific-antibody-collaboration-for-autoimmune-diseases 2026-01-05T13:17:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/earendil-labs-partners-with-sanofi-in-2-56-billion-ai-driven-bispecific-antibody-collaboration-for-autoimmune-diseases 2026-01-05T13:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/alcanza-clinical-research-expands-network-through-strategic-acquisition-of-tampa-bay-medical-research 2026-01-05T12:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcanza-clinical-research-expands-network-through-strategic-acquisition-of-tampa-bay-medical-research 2026-01-05T12:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/scinopharm-becomes-first-taiwan-company-to-win-fda-approval-for-complex-multiple-sclerosis-treatment 2026-01-05T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinopharm-becomes-first-taiwan-company-to-win-fda-approval-for-complex-multiple-sclerosis-treatment 2026-01-05T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-plus-pembrolizumab-shows-24-response-rate-in-recurrent-ovarian-cancer 2026-01-05T08:41:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-s-bi-1808-plus-pembrolizumab-shows-24-response-rate-in-recurrent-ovarian-cancer 2026-01-05T08:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-develops-ai-platform-for-b-cell-reactive-cancer-vaccines-plans-2027-clinical-trials 2026-01-05T08:41:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-develops-ai-platform-for-b-cell-reactive-cancer-vaccines-plans-2027-clinical-trials 2026-01-05T08:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-receives-fda-clearance-for-first-in-class-crispr-gene-therapy-trial-in-tgfbi-corneal-dystrophy 2026-01-05T08:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneditbio-receives-fda-clearance-for-first-in-class-crispr-gene-therapy-trial-in-tgfbi-corneal-dystrophy 2026-01-05T08:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-advance-degrader-antibody-conjugate-platform 2026-01-05T06:39:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-advance-degrader-antibody-conjugate-platform 2026-01-05T06:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-rejuvenating-aging-intestines-in-preclinical-study 2026-01-05T06:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-for-rejuvenating-aging-intestines-in-preclinical-study 2026-01-05T06:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-body-radiotherapy-shows-promise-for-oligometastatic-cancer-treatment-without-systemic-therapy 2026-01-05T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-body-radiotherapy-shows-promise-for-oligometastatic-cancer-treatment-without-systemic-therapy 2026-01-05T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/datasea-partners-with-chinese-bci-company-to-advance-acoustic-enhanced-brain-computer-interface-technology 2026-01-04T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datasea-partners-with-chinese-bci-company-to-advance-acoustic-enhanced-brain-computer-interface-technology 2026-01-04T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/south-korean-biopharma-sector-gains-global-momentum-with-4-2-billion-in-licensing-deals 2026-01-04T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korean-biopharma-sector-gains-global-momentum-with-4-2-billion-in-licensing-deals 2026-01-04T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/novel-microneedle-patch-combines-zerumbone-and-icg-for-dual-mode-melanoma-therapy 2026-01-04T13:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-microneedle-patch-combines-zerumbone-and-icg-for-dual-mode-melanoma-therapy 2026-01-04T13:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/beaver-trial-demonstrates-efficacy-of-binimetinib-encorafenib-combination-in-advanced-non-v600e-braf-mutated-tumors 2026-01-04T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beaver-trial-demonstrates-efficacy-of-binimetinib-encorafenib-combination-in-advanced-non-v600e-braf-mutated-tumors 2026-01-04T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cancer-vaccine-using-blood-cleaning-technology-enters-phase-1-trial-for-ovarian-cancer 2026-01-04T06:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cancer-vaccine-using-blood-cleaning-technology-enters-phase-1-trial-for-ovarian-cancer 2026-01-04T06:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/plant-derived-extracellular-vesicles-enable-itraconazole-delivery-across-blood-brain-barrier-for-glioblastoma-treatment 2026-01-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plant-derived-extracellular-vesicles-enable-itraconazole-delivery-across-blood-brain-barrier-for-glioblastoma-treatment 2026-01-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuralink-expands-human-trials-to-21-participants-as-musk-announces-next-generation-brain-implant 2026-01-04T04:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralink-expands-human-trials-to-21-participants-as-musk-announces-next-generation-brain-implant 2026-01-04T04:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/lipid-nanoparticles-enable-durable-crispr-gene-editing-in-muscle-stem-cells-for-duchenne-muscular-dystrophy 2026-01-04T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipid-nanoparticles-enable-durable-crispr-gene-editing-in-muscle-stem-cells-for-duchenne-muscular-dystrophy 2026-01-04T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-trial-demonstrates-safety-and-efficacy-of-autologous-cd133-stem-cell-therapy-for-asherman-syndrome 2026-01-03T22:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-2-trial-demonstrates-safety-and-efficacy-of-autologous-cd133-stem-cell-therapy-for-asherman-syndrome 2026-01-03T22:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-brainspace-s-intellidrop-automated-brain-fluid-management-system 2026-01-03T20:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-brainspace-s-intellidrop-automated-brain-fluid-management-system 2026-01-03T20:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/live-tumor-fragment-platform-enables-real-time-assessment-of-immunotherapy-responses-in-cancer-patients 2026-01-03T18:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/live-tumor-fragment-platform-enables-real-time-assessment-of-immunotherapy-responses-in-cancer-patients 2026-01-03T18:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/genotype-guided-warfarin-dosing-reduces-dose-adjustments-in-asian-patients-across-multiple-subgroups 2026-01-03T12:23:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genotype-guided-warfarin-dosing-reduces-dose-adjustments-in-asian-patients-across-multiple-subgroups 2026-01-03T12:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-expedited-marketing-authorization-for-altria-s-on-plus-nicotine-pouches 2026-01-03T08:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-expedited-marketing-authorization-for-altria-s-on-plus-nicotine-pouches 2026-01-03T08:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-submits-clinical-trial-application-for-srp-1005-huntington-s-disease-treatment 2026-01-03T03:24:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-submits-clinical-trial-application-for-srp-1005-huntington-s-disease-treatment 2026-01-03T03:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-to-update-fda-ind-status-for-novel-mebufotenin-therapy-gh001-in-treatment-resistant-depression 2026-01-03T01:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-to-update-fda-ind-status-for-novel-mebufotenin-therapy-gh001-in-treatment-resistant-depression 2026-01-03T01:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/dcc-3009-phase-1-2-trial-targets-resistance-mutations-in-advanced-gist-patients 2026-01-02T21:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dcc-3009-phase-1-2-trial-targets-resistance-mutations-in-advanced-gist-patients 2026-01-02T21:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-optimal-androgen-deprivation-therapy-duration-for-localized-prostate-cancer-treatment 2026-01-02T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-optimal-androgen-deprivation-therapy-duration-for-localized-prostate-cancer-treatment 2026-01-02T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-trial-aims-to-replace-opioids-for-cancer-treatment-related-mucositis-pain 2026-01-02T20:24:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabapentin-trial-aims-to-replace-opioids-for-cancer-treatment-related-mucositis-pain 2026-01-02T20:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-promise-for-alcohol-use-disorder-treatment-in-emerging-research 2026-01-02T20:24:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-promise-for-alcohol-use-disorder-treatment-in-emerging-research 2026-01-02T20:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-zapomeran-kostaive-first-self-amplifying-mrna-covid-19-vaccine-for-adults 2026-01-02T17:25:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-zapomeran-kostaive-first-self-amplifying-mrna-covid-19-vaccine-for-adults 2026-01-02T17:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-equity-partners-with-njs-foresight-bio-advisory-to-accelerate-solid-form-patent-out-licensing 2026-01-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdt-equity-partners-with-njs-foresight-bio-advisory-to-accelerate-solid-form-patent-out-licensing 2026-01-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-appoints-dr-jason-litten-as-chief-medical-officer-to-advance-oncolytic-immunotherapy-olvi-vec 2026-01-02T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genelux-appoints-dr-jason-litten-as-chief-medical-officer-to-advance-oncolytic-immunotherapy-olvi-vec 2026-01-02T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/gubra-expands-facilities-by-70-to-support-growing-peptide-drug-pipeline-and-cro-operations 2026-01-02T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gubra-expands-facilities-by-70-to-support-growing-peptide-drug-pipeline-and-cro-operations 2026-01-02T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-bacteria-burden-emerges-as-key-predictor-of-immunotherapy-resistance-in-head-and-neck-cancer 2026-01-02T12:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-bacteria-burden-emerges-as-key-predictor-of-immunotherapy-resistance-in-head-and-neck-cancer 2026-01-02T12:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-padcev-shows-strong-phase-3-results-in-bladder-cancer-validating-43-billion-seagen-acquisition 2026-01-02T09:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-padcev-shows-strong-phase-3-results-in-bladder-cancer-validating-43-billion-seagen-acquisition 2026-01-02T09:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/neovii-pharmaceuticals-appoints-frederic-prince-as-new-ceo-following-christian-loss-s-retirement 2026-01-02T08:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neovii-pharmaceuticals-appoints-frederic-prince-as-new-ceo-following-christian-loss-s-retirement 2026-01-02T08:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/adalta-secures-exclusive-global-rights-to-novel-car-t-therapy-bzds1901-for-mesothelioma-treatment 2026-01-02T05:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalta-secures-exclusive-global-rights-to-novel-car-t-therapy-bzds1901-for-mesothelioma-treatment 2026-01-02T05:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-drug-discovery-reaches-3-billion-milestone-as-isomorphic-labs-partners-with-eli-lilly-and-novartis 2026-01-02T01:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-drug-discovery-reaches-3-billion-milestone-as-isomorphic-labs-partners-with-eli-lilly-and-novartis 2026-01-02T01:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-phase-4-study-testing-switch-from-tafamidis-to-acoramidis-in-attr-cm-patients 2026-01-02T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-phase-4-study-testing-switch-from-tafamidis-to-acoramidis-in-attr-cm-patients 2026-01-02T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-combined-with-hormone-therapy-shows-35-greater-weight-loss-in-postmenopausal-women 2026-01-01T23:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-combined-with-hormone-therapy-shows-35-greater-weight-loss-in-postmenopausal-women 2026-01-01T23:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-patient-achieves-transfusion-independence-following-crispr-gene-therapy-for-beta-thalassaemia 2026-01-01T21:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-patient-achieves-transfusion-independence-following-crispr-gene-therapy-for-beta-thalassaemia 2026-01-01T21:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-upholds-helsinn-s-anti-nausea-drug-patent-dismisses-zydus-challenge 2026-01-01T18:24:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-upholds-helsinn-s-anti-nausea-drug-patent-dismisses-zydus-challenge 2026-01-01T18:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-subsidiary-acquires-khandelwal-labs-non-oncology-portfolio-for-325-crore 2026-01-01T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-subsidiary-acquires-khandelwal-labs-non-oncology-portfolio-for-325-crore 2026-01-01T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/xortx-highlights-breakthrough-genetic-research-doubling-known-gout-risk-factors-to-410 2026-01-01T16:25:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xortx-highlights-breakthrough-genetic-research-doubling-known-gout-risk-factors-to-410 2026-01-01T16:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/immunoforge-seeks-global-partners-for-fda-cleared-rare-disease-therapies-at-jpm-2026 2026-01-01T09:24:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoforge-seeks-global-partners-for-fda-cleared-rare-disease-therapies-at-jpm-2026 2026-01-01T09:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/bioengineered-viruses-enable-precise-rna-editing-in-macrophages-to-combat-sepsis 2026-01-01T04:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioengineered-viruses-enable-precise-rna-editing-in-macrophages-to-combat-sepsis 2026-01-01T04:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-receives-fda-priority-review-for-axs-05-in-alzheimer-s-disease-agitation 2026-01-01T02:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-therapeutics-receives-fda-priority-review-for-axs-05-in-alzheimer-s-disease-agitation 2026-01-01T02:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-stock-surges-131-following-fda-acceptance-of-resubmitted-rp1-application-for-advanced-melanoma 2026-01-01T02:25:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-stock-surges-131-following-fda-acceptance-of-resubmitted-rp1-application-for-advanced-melanoma 2026-01-01T02:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/next-day-hiv-viral-load-testing-fails-to-improve-treatment-uptake-in-clinical-trial 2026-01-01T00:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-day-hiv-viral-load-testing-fails-to-improve-treatment-uptake-in-clinical-trial 2026-01-01T00:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-secures-strategic-manufacturing-partnership-to-cut-production-costs-by-40 2025-12-31T23:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-secures-strategic-manufacturing-partnership-to-cut-production-costs-by-40 2025-12-31T23:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-modernizes-drug-pricing-framework-with-new-cmed-regulation-effective-april-2026 2025-12-31T22:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-modernizes-drug-pricing-framework-with-new-cmed-regulation-effective-april-2026 2025-12-31T22:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-1-1b-deal-for-zelgen-s-dll3-targeting-cancer-therapy 2025-12-31T21:26:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-secures-1-1b-deal-for-zelgen-s-dll3-targeting-cancer-therapy 2025-12-31T21:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-receives-usda-approval-for-befrena-anti-il31-monoclonal-antibody-for-canine-dermatitis 2025-12-31T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elanco-receives-usda-approval-for-befrena-anti-il31-monoclonal-antibody-for-canine-dermatitis 2025-12-31T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-patent-trials-set-for-2026-include-wegovy-and-covid-19-vaccine-technologies 2025-12-31T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-patent-trials-set-for-2026-include-wegovy-and-covid-19-vaccine-technologies 2025-12-31T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/emmaus-life-sciences-grants-exclusive-north-american-rights-for-sickle-cell-drug-endari-to-neoimmunetech 2025-12-31T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emmaus-life-sciences-grants-exclusive-north-american-rights-for-sickle-cell-drug-endari-to-neoimmunetech 2025-12-31T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/xlife-sciences-partners-twelve-biotech-companies-with-grupo-landsteiner-plans-nasdaq-listing-for-2026 2025-12-31T16:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xlife-sciences-partners-twelve-biotech-companies-with-grupo-landsteiner-plans-nasdaq-listing-for-2026 2025-12-31T16:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-secures-40-million-funding-to-advance-ozuriftamab-vedotin-into-phase-3-trial-for-oropharyngeal-cancer 2025-12-31T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-secures-40-million-funding-to-advance-ozuriftamab-vedotin-into-phase-3-trial-for-oropharyngeal-cancer 2025-12-31T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-evolut-low-risk-data-shows-higher-reintervention-rates-for-tavr-vs-surgery-in-low-risk-aortic-stenosis-patients 2025-12-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-year-evolut-low-risk-data-shows-higher-reintervention-rates-for-tavr-vs-surgery-in-low-risk-aortic-stenosis-patients 2025-12-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/male-contraceptive-pill-yct-529-completes-first-human-safety-trial 2025-12-31T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/male-contraceptive-pill-yct-529-completes-first-human-safety-trial 2025-12-31T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-files-european-marketing-application-for-novel-antibiotic-wck-5222-to-combat-drug-resistant-infections 2025-12-31T12:24:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-files-european-marketing-application-for-novel-antibiotic-wck-5222-to-combat-drug-resistant-infections 2025-12-31T12:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/co-diagnostics-secures-first-patent-for-point-of-care-pcr-platform-in-australia 2025-12-31T09:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/co-diagnostics-secures-first-patent-for-point-of-care-pcr-platform-in-australia 2025-12-31T09:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-inotuzumab-ozogamicin-achieves-57-remission-rate-in-relapsed-refractory-b-all-despite-dose-modifications 2025-12-31T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-inotuzumab-ozogamicin-achieves-57-remission-rate-in-relapsed-refractory-b-all-despite-dose-modifications 2025-12-31T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/capsovision-submits-fda-application-for-ai-enhanced-capsule-endoscopy-system 2025-12-31T08:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsovision-submits-fda-application-for-ai-enhanced-capsule-endoscopy-system 2025-12-31T08:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/arovella-submits-ind-application-for-first-in-human-trial-of-car-inkt-cell-therapy-ala-101 2025-12-31T05:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arovella-submits-ind-application-for-first-in-human-trial-of-car-inkt-cell-therapy-ala-101 2025-12-31T05:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-pdab-sets-first-upper-payment-limits-for-diabetes-drugs-as-state-level-price-control-model-gains-momentum 2025-12-31T02:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-pdab-sets-first-upper-payment-limits-for-diabetes-drugs-as-state-level-price-control-model-gains-momentum 2025-12-31T02:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-faces-fda-delay-for-setmelanotide-in-hypothalamic-obesity-as-stock-retreats-from-2025-highs 2025-12-31T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-faces-fda-delay-for-setmelanotide-in-hypothalamic-obesity-as-stock-retreats-from-2025-highs 2025-12-31T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/two-autophagy-targeting-biotech-companies-advance-neurodegeneration-therapies-to-human-trials 2025-12-31T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-autophagy-targeting-biotech-companies-advance-neurodegeneration-therapies-to-human-trials 2025-12-31T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-completes-bla-submission-for-first-gene-therapy-targeting-glycogen-storage-disease-type-ia 2025-12-31T00:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-completes-bla-submission-for-first-gene-therapy-targeting-glycogen-storage-disease-type-ia 2025-12-31T00:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/sinopia-biosciences-secures-nih-grant-to-advance-ai-powered-drug-discovery-platform 2025-12-30T19:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinopia-biosciences-secures-nih-grant-to-advance-ai-powered-drug-discovery-platform 2025-12-30T19:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-secures-israeli-patent-for-novel-opioid-pea-combination-to-reduce-side-effects 2025-12-30T18:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-labs-secures-israeli-patent-for-novel-opioid-pea-combination-to-reduce-side-effects 2025-12-30T18:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-secures-7-million-in-registered-direct-offering-to-advance-phase-3-dna-mediated-immunotherapy 2025-12-30T17:26:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-secures-7-million-in-registered-direct-offering-to-advance-phase-3-dna-mediated-immunotherapy 2025-12-30T17:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/weizmann-institute-develops-novel-immunotherapy-strategy-targeting-drug-resistant-cancer-mutations 2025-12-30T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weizmann-institute-develops-novel-immunotherapy-strategy-targeting-drug-resistant-cancer-mutations 2025-12-30T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-reports-encouraging-post-hoc-analyses-for-vilobelimab-in-pyoderma-gangrenosum-despite-phase-3-trial-termination 2025-12-30T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflarx-reports-encouraging-post-hoc-analyses-for-vilobelimab-in-pyoderma-gangrenosum-despite-phase-3-trial-termination 2025-12-30T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/uni-bio-science-forms-strategic-alliance-to-advance-growth-factor-combination-therapies-in-regenerative-medicine 2025-12-30T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uni-bio-science-forms-strategic-alliance-to-advance-growth-factor-combination-therapies-in-regenerative-medicine 2025-12-30T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/derazantinib-enhances-gemcitabine-efficacy-in-pancreatic-cancer-by-suppressing-nf-kb-and-mapk-pathways 2025-12-30T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/derazantinib-enhances-gemcitabine-efficacy-in-pancreatic-cancer-by-suppressing-nf-kb-and-mapk-pathways 2025-12-30T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-triple-combination-cancer-therapy-with-nmpa-approval-for-hlx43-adc-study 2025-12-30T13:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-advances-triple-combination-cancer-therapy-with-nmpa-approval-for-hlx43-adc-study 2025-12-30T13:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-drugs-show-promise-for-addiction-treatment-in-early-clinical-studies 2025-12-30T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-drugs-show-promise-for-addiction-treatment-in-early-clinical-studies 2025-12-30T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-acquires-full-evrysdi-royalty-rights-for-240-million-securing-100-interest-in-leading-sma-treatment 2025-12-30T06:26:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-acquires-full-evrysdi-royalty-rights-for-240-million-securing-100-interest-in-leading-sma-treatment 2025-12-30T06:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-blocks-hhs-340b-drug-rebate-pilot-program-protecting-hospital-discount-system 2025-12-30T03:47:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-blocks-hhs-340b-drug-rebate-pilot-program-protecting-hospital-discount-system 2025-12-30T03:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/subgroup-analysis-of-phase-3-focus-study-reveals-optimal-patient-selection-for-melphalan-hepatic-delivery-system-in-uveal-melanoma 2025-12-30T03:26:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subgroup-analysis-of-phase-3-focus-study-reveals-optimal-patient-selection-for-melphalan-hepatic-delivery-system-in-uveal-melanoma 2025-12-30T03:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-discontinues-kras-g12c-trial-to-focus-on-promising-g12d-inhibitor-with-69-response-rate 2025-12-30T03:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verastem-discontinues-kras-g12c-trial-to-focus-on-promising-g12d-inhibitor-with-69-response-rate 2025-12-30T03:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-herbal-formula-shows-superior-kidney-function-preservation-in-diabetic-kidney-disease-trial 2025-12-29T23:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-chinese-herbal-formula-shows-superior-kidney-function-preservation-in-diabetic-kidney-disease-trial 2025-12-29T23:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/bluejay-diagnostics-completes-commercial-scale-il-6-antibody-production-for-sepsis-diagnostic-platform 2025-12-29T23:28:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluejay-diagnostics-completes-commercial-scale-il-6-antibody-production-for-sepsis-diagnostic-platform 2025-12-29T23:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/imunon-reports-strong-phase-3-ovation-3-enrollment-progress-as-imnn-001-shows-promise-in-advanced-ovarian-cancer-treatment 2025-12-29T23:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imunon-reports-strong-phase-3-ovation-3-enrollment-progress-as-imnn-001-shows-promise-in-advanced-ovarian-cancer-treatment 2025-12-29T23:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/work-medical-receives-regulatory-approval-for-ai-powered-blood-cell-morphology-analyzer 2025-12-29T23:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/work-medical-receives-regulatory-approval-for-ai-powered-blood-cell-morphology-analyzer 2025-12-29T23:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-and-navigo-proteins-terminate-radiotheranostics-collaboration 2025-12-29T23:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-and-navigo-proteins-terminate-radiotheranostics-collaboration 2025-12-29T23:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-researchers-discover-breast-cancer-drug-palbociclib-overcomes-venetoclax-resistance-in-acute-myeloid-leukemia 2025-12-29T22:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ohsu-researchers-discover-breast-cancer-drug-palbociclib-overcomes-venetoclax-resistance-in-acute-myeloid-leukemia 2025-12-29T22:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-s-setrusumab-fails-two-phase-3-trials-for-rare-bone-disease-shares-plummet-43 2025-12-29T22:24:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-s-setrusumab-fails-two-phase-3-trials-for-rare-bone-disease-shares-plummet-43 2025-12-29T22:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-as-clinical-guidelines-support-intravascular-imaging 2025-12-29T19:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-as-clinical-guidelines-support-intravascular-imaging 2025-12-29T19:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-secures-exclusive-rights-to-novel-fortnightly-glp-1-receptor-agonist-bofanglutide-for-indian-market 2025-12-29T19:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-secures-exclusive-rights-to-novel-fortnightly-glp-1-receptor-agonist-bofanglutide-for-indian-market 2025-12-29T19:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/cbih-pursues-patent-for-cannabinoid-based-therapy-targeting-opioid-addiction-recovery 2025-12-29T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbih-pursues-patent-for-cannabinoid-based-therapy-targeting-opioid-addiction-recovery 2025-12-29T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/lund-university-researchers-identify-statin-phenothiazine-combination-as-potential-neuroblastoma-treatment-using-machine-learning 2025-12-29T19:40:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lund-university-researchers-identify-statin-phenothiazine-combination-as-potential-neuroblastoma-treatment-using-machine-learning 2025-12-29T19:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-neffy-as-first-community-use-epinephrine-product-for-severe-allergic-reactions 2025-12-29T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-neffy-as-first-community-use-epinephrine-product-for-severe-allergic-reactions 2025-12-29T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/azenta-divests-b-medical-systems-for-63-million-to-focus-on-core-life-sciences-portfolio 2025-12-29T19:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azenta-divests-b-medical-systems-for-63-million-to-focus-on-core-life-sciences-portfolio 2025-12-29T19:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/setrusumab-phase-3-trials-in-osteogenesis-imperfecta-show-mixed-results-across-age-groups 2025-12-29T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/setrusumab-phase-3-trials-in-osteogenesis-imperfecta-show-mixed-results-across-age-groups 2025-12-29T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/unicycive-therapeutics-resubmits-nda-for-novel-phosphate-binder-targeting-hyperphosphatemia-in-dialysis-patients 2025-12-29T19:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unicycive-therapeutics-resubmits-nda-for-novel-phosphate-binder-targeting-hyperphosphatemia-in-dialysis-patients 2025-12-29T19:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-discontinues-acasunlimab-development-to-focus-on-late-stage-pipeline-programs 2025-12-29T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-discontinues-acasunlimab-development-to-focus-on-late-stage-pipeline-programs 2025-12-29T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/theriva-biologics-receives-ema-scientific-advice-for-vcn-01-phase-3-trial-in-metastatic-pancreatic-cancer 2025-12-29T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theriva-biologics-receives-ema-scientific-advice-for-vcn-01-phase-3-trial-in-metastatic-pancreatic-cancer 2025-12-29T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/cel-sci-advances-multikine-toward-registration-with-212-patient-confirmatory-study-for-head-and-neck-cancer 2025-12-29T19:30:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cel-sci-advances-multikine-toward-registration-with-212-patient-confirmatory-study-for-head-and-neck-cancer 2025-12-29T19:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/zevra-therapeutics-expands-global-access-to-miplyffa-through-distribution-partnership-with-uniphar 2025-12-29T19:30:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zevra-therapeutics-expands-global-access-to-miplyffa-through-distribution-partnership-with-uniphar 2025-12-29T19:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-advances-tnx-4800-monoclonal-antibody-for-lyme-disease-prevention-with-fda-meeting-planned-for-2026 2025-12-29T19:30:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-advances-tnx-4800-monoclonal-antibody-for-lyme-disease-prevention-with-fda-meeting-planned-for-2026 2025-12-29T19:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-secures-20-million-funding-to-advance-fibromyalgia-treatment-and-pipeline-development 2025-12-29T19:29:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-secures-20-million-funding-to-advance-fibromyalgia-treatment-and-pipeline-development 2025-12-29T19:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-eur2-9-million-in-latest-fundraising-round-for-gene-therapy-development 2025-12-29T18:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-secures-eur2-9-million-in-latest-fundraising-round-for-gene-therapy-development 2025-12-29T18:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-divests-1-6-billion-apac-operations-to-focus-on-glp-1-drug-production 2025-12-29T18:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-pharmacare-divests-1-6-billion-apac-operations-to-focus-on-glp-1-drug-production 2025-12-29T18:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/adlai-nortye-partners-with-ask-pharm-in-230-million-deal-for-pan-ras-inhibitor-an9025-in-greater-china 2025-12-29T18:26:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adlai-nortye-partners-with-ask-pharm-in-230-million-deal-for-pan-ras-inhibitor-an9025-in-greater-china 2025-12-29T18:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-therapeutics-partners-with-eirgenix-to-license-continuous-biomanufacturing-platform-for-affordable-biologics 2025-12-29T18:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcenta-therapeutics-partners-with-eirgenix-to-license-continuous-biomanufacturing-platform-for-affordable-biologics 2025-12-29T18:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/intas-pharmaceuticals-partners-with-integrimedical-to-launch-india-s-first-needle-free-ivf-injection-system 2025-12-29T15:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intas-pharmaceuticals-partners-with-integrimedical-to-launch-india-s-first-needle-free-ivf-injection-system 2025-12-29T15:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/corteva-and-hexagon-bio-launch-multi-million-dollar-joint-venture-for-nature-inspired-agricultural-and-pharmaceutical-solutions 2025-12-29T14:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corteva-and-hexagon-bio-launch-multi-million-dollar-joint-venture-for-nature-inspired-agricultural-and-pharmaceutical-solutions 2025-12-29T14:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/smart-nanoparticles-enable-disease-responsive-gene-therapy-for-osteoarthritis 2025-12-29T13:24:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-nanoparticles-enable-disease-responsive-gene-therapy-for-osteoarthritis 2025-12-29T13:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharmaceutical-faces-market-skepticism-over-200-million-green-valley-acquisition-amid-regulatory-concerns 2025-12-29T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosun-pharmaceutical-faces-market-skepticism-over-200-million-green-valley-acquisition-amid-regulatory-concerns 2025-12-29T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/who-prequalifies-first-covid-19-rapid-antigen-tests-for-long-term-global-use 2025-12-29T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-prequalifies-first-covid-19-rapid-antigen-tests-for-long-term-global-use 2025-12-29T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/catnon-trial-final-results-confirm-adjuvant-temozolomide-benefit-in-idh-mutant-anaplastic-glioma 2025-12-29T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catnon-trial-final-results-confirm-adjuvant-temozolomide-benefit-in-idh-mutant-anaplastic-glioma 2025-12-29T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/news/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9